ADMA
ADMA Biologics, Inc.
Biotechnology · Healthcare · United States
11.75
close · 2026-10-29
value
73
cheaper than peers73
quality
53
stronger fundamentals53
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
caveat margins at their own peak
Value inputs
| measure | company | vs peers |
| cash flow yield, 1 year ago | 5.2% | 95 |
| earnings yield, 1 year ago | 8.6% | 95 |
| price to sales | 4.21× | 79 |
| cash flow yield, 2 years ago | 0.2% | 77 |
| earnings yield, latest year | 6.3% | 77 |
| earnings yield, 2 years ago | -1.4% | 77 |
| forward P/E | 12.46× | 74 |
| cash flow yield, latest year | 1.3% | 68 |
| earnings yield, 3 years ago | -3.5% | 68 |
| cash flow yield, 3 years ago | -3.5% | 50 |
| price to book | 6.49× | 30 |
| EV to EBITDA | 203.76× | 7 |
12 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 43.3% | 93 |
| operating margin | -123.4% | 52 |
| revenue growth | 15.9% | 47 |
| debt to equity | 110.7% | 22 |
4 of 4 measures available
Facts
| market cap | $3B |
| free cash flow | $58.4M |
| employees | 640 |
| first trade | 2013-10-17 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-05 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 0.60 | 0.81 | -0.13 | -0.33 |
| free cash flow | $27.5M | $110.1M | $3.8M | -$73.4M |
| net income | $146.9M | $197.7M | -$28.2M | -$65.9M |
| revenue | $510.2M | $426.5M | $258.2M | $154.1M |
| unusual items | -$3.3M | -$1.2M | -$26.2M | -$6.7M |